KPAX002-1: Parkinson's Disease

Phase 2 ready. K-PAX is ready to implement its phase 2 program to demonstrate the safety and efficacy of KPAX002 as a treatment for Parkinson's disease fatigue and excessive daytime sleepiness. These symptoms represent a key unmet need in the treatment of this condition. 

KPAX002-2: Alzheimer's Disease

Phase 2 ready. We are ready to implement a proof-of-concept trial to demonstrate the safety and efficacy of KPAX002 as a treatment for the decreased alertness and impaired cognitive symptoms of Alzheimer's disease.

KPAX002-3:  Myalgic Encephalomyelitis/CFS 

Phase 3 ready. We have successfully completed phase 1 and phase 2 trials in patients with ME/CFS and are now ready to implement our pivotal phase 3 trial. The FDA has issued a draft guidance to industry and is on record as being highly motivated to approve a first treatment for this disease. KPAX002 is the leading candidate ready to take advantage of this unique opportunity. KPAX002 possesses strong IP protection through 2032.

Questions regarding partnering opportunities can be directed to K-PAX Pharmaceuticals' Director of Operations, Anne Lahaderne at: This email address is being protected from spambots. You need JavaScript enabled to view it. or by calling (415) 381-7655.